GO
Loading...

Amgen Inc

More

  • Final Glance: Biotechnology companies Thursday, 21 Aug 2014 | 6:08 PM ET

    Amgen Inc. fell$. 15 or. 1 percent, to $132.53. Biogen Idec fell $3.93 or 1.1 percent, to $338.65. Celgene Corp. fell$. 34 or. 4 percent, to $91.66.

  • Midday Glance: Biotechnology companies Thursday, 21 Aug 2014 | 1:22 PM ET

    Amgen Inc. rose$. 03 or percent, to $132.71. Biogen Idec fell $2.14 or. 6 percent, to $340.45. Celgene Corp. rose$. 02 or percent, to $92.02.

  • Aug 21- An experimental new psoriasis treatment from Eli Lilly and Co proved superior to Amgen Inc's blockbuster Enbrel, drawing it closer to a potential marketing battle with new products being developed by Amgen and Novartis AG.

  • Lilly psoriasis drug fares well in late-stage test Thursday, 21 Aug 2014 | 8:55 AM ET

    INDIANAPOLIS— Drugmaker Eli Lilly and Co. said its potential psoriasis treatment fared better than both a fake drug and a competitor's product during late-stage testing on patients with the most common form of the skin disease.

  • Final Glance: Biotechnology companies Wednesday, 20 Aug 2014 | 6:02 PM ET

    Amgen Inc. fell$. 34 or. 3 percent, to $132.68. Biogen Idec fell $3.26 or. 9 percent, to $342.58. Celgene Corp. rose$. 64 or. 7 percent, to $92.00.

  • Midday Glance: Biotechnology companies Wednesday, 20 Aug 2014 | 1:49 PM ET

    Amgen Inc. fell$. 35 or. 3 percent, to $132.67. Biogen Idec fell $2.66 or. 8 percent, to $343.18. Celgene Corp. rose $1.38 or 1.5 percent, to $92.74.

  • Early Glance: Biotechnology companies Wednesday, 20 Aug 2014 | 12:21 PM ET

    Amgen Inc. fell$. 61 or. 5 percent, to $132.41. Biogen Idec fell $1.68 or. 5 percent, to $344.16. Celgene Corp. rose $1.47 or 1.6 percent, to $92.83.

  • Final Glance: Biotechnology companies Tuesday, 19 Aug 2014 | 6:08 PM ET

    Amgen Inc. fell$. 20 or. 2 percent, to $133.02. Biogen Idec rose $1.24 or. 4 percent, to $345.84. Celgene Corp. rose$. 05 or. 1 percent, to $91.36.

  • Midday Glance: Biotechnology companies Tuesday, 19 Aug 2014 | 4:03 PM ET

    Amgen Inc. fell $1.29 or 1.0 percent, to $131.93. Biogen Idec fell$. 31 or. 1 percent, to $344.29. Celgene Corp. rose$. 10 or. 1 percent, to $91.41.

  • Final Glance: Biotechnology companies Monday, 18 Aug 2014 | 6:02 PM ET

    Amgen Inc. rose$. 42 or. 3 percent, to $133.22. Biogen Idec rose $2.13 or. 6 percent, to $344.60. Celgene Corp. rose $1.71 or 1.9 percent, to $91.31.

  • Early Glance: Biotechnology companies Monday, 18 Aug 2014 | 10:29 AM ET

    Amgen Inc. rose $1.09 or. 8 percent, to $133.89. Biogen Idec rose $3.18 or. 9 percent, to $345.65. Celgene Corp. rose $1.70 or 1.9 percent, to $91.30.

  • LOS ANGELES, Aug 17- Biotech drug production techniques based on plants, which may prove to be faster, higher yielding and cheaper than current methods using mammalian cells, haven't caught on with the biggest pharmaceutical companies.

  • Final Glance: Biotechnology companies Friday, 15 Aug 2014 | 6:16 PM ET

    Amgen Inc. rose$. 94 or. 7 percent, to $132.80. Biogen Idec rose $5.46 or 1.6 percent, to $342.47. Celgene Corp. rose $1.15 or 1.3 percent, to $89.61.

  • Midday Glance: Biotechnology companies Friday, 15 Aug 2014 | 1:15 PM ET

    Amgen Inc. fell$. 50 or. 4 percent, to $131.36. Biogen Idec rose$. 93 or. 3 percent, to $337.94. Celgene Corp. rose$. 77 or. 9 percent, to $89.23.

  • Early Glance: Biotechnology companies Friday, 15 Aug 2014 | 11:21 AM ET

    Amgen Inc. fell$. 65 or. 5 percent, to $131.21. Biogen Idec rose $1.59 or. 5 percent, to $338.60. Celgene Corp. rose $1.25 or 1.4 percent, to $89.71.

  • US STOCKS-Futures point to flat open after recent rally Thursday, 14 Aug 2014 | 8:54 AM ET

    *Cisco down in premarket after results, outlook. NEW YORK, Aug 14- U.S. stock index futures pointed to a flat open on Thursday as investors found few reasons to buy following a sharp rally in the previous session and amid signs of weakness in Europe and ongoing uncertainty over Ukraine.

  • Final Glance: Biotechnology companies Wednesday, 13 Aug 2014 | 6:14 PM ET

    Amgen Inc. rose $1.02 or. 8 percent, to $127.34. Biogen Idec rose $9.68 or 3.0 percent, to $334.64. Celgene Corp. rose $1.97 or 2.3 percent, to $88.41.

  • Aug 13- Amgen Inc's Kyprolis drug failed to show it could extend survival compared to standard care for patients with advanced multiple myeloma, a type of blood cancer that develops in the bone marrow. Shares of Amgen were down 2.1 percent at $124.66 in after-hours trading on Wednesday.

  • Aug 13- A Phase 3 trial of Amgen Inc's Kyprolis drug failed to show it could extend survival compared to standard care for patients with advanced multiple myeloma, a type of blood cancer that develops in the bone marrow. Shares of Amgen were down 2.3 percent at $124.41 in after-hours trading on Wednesday.

  • Midday Glance: Biotechnology companies Wednesday, 13 Aug 2014 | 1:50 PM ET

    Amgen Inc. rose$. 83 or. 7 percent, to $127.15. Biogen Idec rose $8.44 or 2.6 percent, to $333.40. Celgene Corp. rose $1.70 or 2.0 percent, to $88.14.